Rxwire
In the news · 48h FDA 37 Eli Lilly 17 Roche 9 Merck & Co. (MSD) 7 Johnson & Johnson 4 AstraZeneca 3 Novo Nordisk 3 AbbVie 2
Approvals & regulatory · first seen 7h ago, updated 6h ago

FGFR2 inhibitor Lyrfigtu wins FDA approval for bile duct cancer

2 outlets FDA

Nearly two years after licensing Relay Therapeutics Inc.’s oral small-molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), lirafugratinib, Elevar Therapeutics Inc. won U.S. FDA approval under priority review to treat cholangio…

Summary from BioWorld Articles.

Coverage 2 articles · 2 outlets

  1. BioWorld Articles
    FGFR2 inhibitor Lyrfigtu wins FDA approval for bile duct cancer
  2. Endpoints News
    Elevar wins first FDA approval with second-line drug for bile duct cancer